or Try an Advanced Search...

    Technical Analysis for LTRN - Lantern Pharma Inc.

    Grade Last Price % Change Price Change
    F 3.31 5.92% 0.19
    LTRN closed up 5.92 percent on Friday, November 1, 2024, on 49 percent of normal volume.
    Earnings due: Nov 7
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical LTRN trend table...
    Date Alert Name Type % Chg
    Bullish Engulfing Bullish 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    MACD Bearish Signal Line Cross Bearish 5.92%
    BB Squeeze Ended Range Expansion 5.92%
    Below Lower BB Weakness 5.92%
    Down 3 Days in a Row Weakness 5.92%
    Lower Bollinger Band Touch Weakness 5.92%
    Bollinger Band Squeeze Range Contraction 1.53%
    Gapped Down Weakness 1.53%
    Fell Below 20 DMA Bearish -5.16%
    Older End-of-Day Signals for LTRN ...

       Recent Intraday Alerts

    Alert Time
    Up 5% about 18 hours ago
    Possible NR7 about 20 hours ago
    Rose Above Previous Day's High about 21 hours ago
    Up 3% about 22 hours ago
    60 Minute Opening Range Breakout about 22 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    LTRN Chart by TradingView
    Basic chart:

    Profile

    Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-11, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Artificial Intelligence Machine Learning Cybernetics Computational Neuroscience Pharma

    Is LTRN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 31 Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET
    Oct 23 Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
    Oct 21 Lantern Pharma to Host & Participate in Two Public Webinars During October
    Oct 15 Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
    Oct 9 Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ...
    Sep 23 Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers
    Aug 31 Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire
    Aug 12 LTRN: Second Quarter Results
    Aug 10 Lantern Pharma Inc. 2024 Q2 - Results - Earnings Call Presentation
    Aug 10 Lantern Pharma Inc. (LTRN) Q2 2024 Earnings Call Transcript
    See more LTRN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 11.99
    52 Week Low 2.74
    Average Volume 41,914
    200-Day Moving Average 5.02
    50-Day Moving Average 3.71
    20-Day Moving Average 3.45
    10-Day Moving Average 3.38
    Average True Range 0.28
    RSI (14) 43.50
    ADX 30.08
    +DI 10.78
    -DI 21.61
    Chandelier Exit (Long, 3 ATRs) 3.05
    Chandelier Exit (Short, 3 ATRs) 3.88
    Upper Bollinger Bands 3.74
    Lower Bollinger Band 3.16
    Percent B (%b) 0.26
    BandWidth 16.57
    MACD Line -0.12
    MACD Signal Line -0.11
    MACD Histogram -0.0056
    Fundamentals Value
    Market Cap 35.5 Million
    Num Shares 10.7 Million
    EPS -1.39
    Price-to-Earnings (P/E) Ratio -2.38
    Price-to-Sales 0.00
    Price-to-Book 0.98
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.70
    Resistance 3 (R3) 3.66 3.48 3.64
    Resistance 2 (R2) 3.48 3.38 3.51 3.61
    Resistance 1 (R1) 3.40 3.32 3.44 3.44 3.59
    Pivot Point 3.22 3.22 3.25 3.25 3.22
    Support 1 (S1) 3.14 3.12 3.18 3.18 3.03
    Support 2 (S2) 2.96 3.06 2.99 3.01
    Support 3 (S3) 2.88 2.96 2.99
    Support 4 (S4) 2.92